Compare

Mapped vs the alternatives

An honest, side-by-side comparison of mapped against Covidence, Rayyan, RevMan, and EPPI-Reviewer across the systematic-review workflow. We acknowledge each tool's genuine strengths — pick the one that fits your work, not the one with the loudest marketing.

Updated April 2026

Screening + extraction tool

Mapped vs Covidence

Covidence is the most-cited screening tool in the systematic-review literature, with a polished dual-reviewer workflow that's been refined over a decade. For teams whose review consists almost entirely of screening and basic extraction, it's a solid, focused choice.

Feature comparison: mapped vs Covidence
Workflow stepMappedCovidence
Research-question validation (PICOS, gap analysis, PROSPERO)
Yes: 8-stage VALIDATION + Word feasibility report
No: Not in scope
Multi-database literature search (10+ databases)
Yes: PubMed, Cochrane, Scopus, Embase, +6
No: Bring-your-own results
Title/abstract + full-text screening (dual-reviewer)
Yes: Blinded, Cohen's kappa IRR
Yes: Strong, mature workflow
AI-assisted screening
Yes: Classification Engine, confidence-tiered
Limited: AI-assist add-on
Data extraction from PDFs
Yes: Multimodal Engine + scanned-PDF + Sheets sync
Yes: Template-based; manual transcription
Risk of bias (8 tools incl. RoB 2 Cluster, ROBINS-E, QUIPS, AMSTAR 2)
Yes: 8 validated tools, AI-drafted judgments
Limited: RoB 2 only
Meta-analysis (incl. DTA, NMA, GOSH, Baujat)
Yes: R engine, 13 plot types, 600 DPI
No: Export to RevMan/Stata
GRADE assessment + Summary of Findings
Yes: Per-outcome, auto-pulled from RoB + meta
No: External tool
AI manuscript drafting (PRISMA 2020)
Yes: 13-section drafts, 7 journal presets
No: Out of scope

Mapped pricing

Free · Mapped Project $119/project (launch $79) · Mapped Team $199/project (launch $139) · Custom Enterprise

See mapped pricing

Covidence pricing

Free trial · ~$339/year per single review · Institutional plans

See Covidence pricing

Choose mapped if…

  • You need the full eight-step workflow in one place — search through manuscript
  • You're running a meta-analysis (DTA, NMA, or classic intervention)
  • You want AI-assisted RoB judgments with quoted source text
  • You publish per-project rather than per-year (Mapped Project is $119/project list, currently $79 launch pricing — not $339+/year)

Choose Covidence if…

  • Your review is screening-and-extraction only
  • Your team already has decade-long Covidence muscle memory
  • You handle meta-analysis externally in RevMan or Stata anyway
  • Institutional licensing already covers Covidence at zero marginal cost

AI-screening tool

Mapped vs Rayyan

Rayyan pioneered AI-assisted screening for systematic reviews and remains a popular free option. Its keyboard-first screening UI is fast and well-loved, and the free tier is genuinely useful for solo researchers and student projects.

Feature comparison: mapped vs Rayyan
Workflow stepMappedRayyan
Research-question validation
Yes: 8-stage VALIDATION score
No: Not in scope
Multi-database literature search
Yes: 10+ databases, AI query generation
No: Import-only
AI-assisted title/abstract screening
Yes: Classification Engine, confidence-tiered
Yes: Strong, AI-rating filter
Full-text screening with eligibility criteria
Yes: PRISMA-compliant, exclusion-reason tracked
Limited: Basic full-text support
Dual-reviewer with blinded conflict resolution
Yes: Structurally enforced + Cohen's kappa
Yes: Blinded mode available
PDF data extraction
Yes: Multimodal Engine + Google Sheets sync
No: Out of scope
Risk of bias assessment
Yes: 8 validated tools
No: Out of scope
Meta-analysis
Yes: R-based, DTA + NMA, 13 plot types
No: Out of scope
Manuscript drafting
Yes: 13-section drafts, 7 journal presets
No: Out of scope

Mapped pricing

Free · Mapped Project $119/project (launch $79) · Mapped Team $199/project (launch $139) · Custom Enterprise

See mapped pricing

Rayyan pricing

Free tier (limited) · Pro ~$11/month · Teams plans

See Rayyan pricing

Choose mapped if…

  • You want the full review pipeline in one tool — not just screening
  • You need risk of bias, meta-analysis, GRADE, or manuscript output
  • You're running a DTA or NMA review (Rayyan doesn't cover analysis)
  • You'd rather pay per-project than maintain a monthly subscription

Choose Rayyan if…

  • You only need screening (you have other tools for the rest)
  • Free tier is sufficient and budget is the binding constraint
  • You prefer Rayyan's keyboard-first screening UI specifically
  • You're a solo researcher or student doing a one-off small review

Cochrane meta-analysis software

Mapped vs RevMan (Cochrane)

RevMan is the de-facto Cochrane tool for systematic reviews and intervention meta-analyses, with deep methodological alignment to Cochrane's own handbook and reviewer expectations. For Cochrane-author teams, it's the canonical workflow.

Feature comparison: mapped vs RevMan (Cochrane)
Workflow stepMappedRevMan (Cochrane)
Research-question validation
Yes: VALIDATION + PROSPERO + gap analysis
No: External
Multi-database search
Yes: 10+ databases simultaneously
No: Bring-your-own
Dual-reviewer screening
Yes: Blinded, AI-accelerated
Limited: Light support; teams use Covidence + RevMan
Data extraction from PDFs
Yes: AI multimodal extraction
Limited: Manual entry
Risk of bias (RoB 2)
Yes: Plus 7 other tools (Cluster, ROBINS-I, ROBINS-E, QUADAS-2, QUIPS, NOS, AMSTAR 2)
Yes: Strong RoB 2 implementation
Intervention meta-analysis (forest, funnel)
Yes: Plus DTA, NMA, GOSH, Baujat, drapery
Yes: Excellent for Cochrane-style intervention reviews
Diagnostic test accuracy meta-analysis
Yes: Bivariate (mada), SROC, coupled forest
Limited: DTA support limited
Network meta-analysis
Yes: netmeta, league tables, rankograms
No: Use external NMA tool
GRADE + Summary of Findings
Yes: Per-outcome, auto-pulled from RoB + meta
Limited: Via GRADEpro GDT integration
Manuscript drafting
Yes: 13-section drafts, 7 journal presets
Limited: Cochrane-format report

Mapped pricing

Free · Mapped Project $119/project (launch $79) · Mapped Team $199/project (launch $139) · Custom Enterprise

See mapped pricing

RevMan (Cochrane) pricing

Free for non-commercial use · Cochrane authors free · Commercial license required for non-Cochrane commercial use

See RevMan (Cochrane) pricing

Choose mapped if…

  • You're running DTA or NMA (RevMan's coverage there is limited)
  • You want AI-assisted extraction, screening, and manuscript drafting
  • Your review will be published outside the Cochrane Library
  • You want 13 plot types including GOSH, Baujat, drapery, and funnel variants at 600 DPI

Choose RevMan (Cochrane) if…

  • You're authoring a Cochrane Review (RevMan is the canonical workflow)
  • Your review is intervention-only and methodologically straightforward
  • Your team already has deep RevMan + GRADEpro GDT experience
  • Cochrane Editorial Unit acceptance is a hard requirement

Full-pipeline review tool

Mapped vs EPPI-Reviewer

EPPI-Reviewer (UCL) is the most feature-complete academic alternative to mapped — strong qualitative-coding tools, machine-learning classifiers, and a long methodological track record across multiple review types. It's the closest 1:1 alternative on workflow breadth.

Feature comparison: mapped vs EPPI-Reviewer
Workflow stepMappedEPPI-Reviewer
Research-question validation
Yes: VALIDATION score, gap analysis, PROSPERO
No: Out of scope
Multi-database search
Yes: 10+ databases, AI query generation
Yes: Federated search; manual config
Dual-reviewer screening with AI
Yes: Classification Engine, blinded, Cohen's kappa
Yes: ML classifiers, dual-reviewer
PDF data extraction
Yes: Multimodal Engine + scanned-PDF + Sheets
Limited: Manual + structured forms
Qualitative coding / line-by-line analysis
Limited: Free-text fields, no inductive coding
Yes: Strong qualitative tooling
Risk of bias (multiple tools)
Yes: 8 tools, AI-drafted judgments
Yes: Tool catalogue, manual entry
Meta-analysis (DTA, NMA, plot variants)
Yes: R engine, 13 plots, 600 DPI exports
Limited: Basic statistical synthesis
GRADE assessment
Yes: Per-outcome SoF tables
Limited: External
AI manuscript drafting
Yes: 13-section drafts, 7 journal presets
No: Out of scope
Cohen's kappa IRR + immutable audit trail
Yes: Built-in, structurally enforced
Yes: IRR + activity log

Mapped pricing

Free · Mapped Project $119/project (launch $79) · Mapped Team $199/project (launch $139) · Custom Enterprise

See mapped pricing

EPPI-Reviewer pricing

~£28–£55 per single user / month · institutional licenses

See EPPI-Reviewer pricing

Choose mapped if…

  • You're running quantitative reviews (intervention, prognostic, DTA, NMA)
  • You want AI-drafted manuscript output that follows PRISMA 2020
  • You need 600 DPI publication-ready plots (rainforest, drapery, GOSH, Baujat)
  • You'd rather pay per-project than maintain a monthly per-user subscription

Choose EPPI-Reviewer if…

  • Your review is qualitative or mixed-methods with deep inductive coding
  • You're at an institution with existing EPPI-Reviewer training and licensing
  • You need EPPI's specific machine-learning classifier customization workflow
  • Your evidence-synthesis methodology is policy-research-flavored rather than medical

Frequently asked questions

Which is the best systematic-review tool for screening?
If screening is your only need, Covidence is excellent and Rayyan is solid (and free at the entry tier). If you want screening to feed into extraction, RoB, meta-analysis, GRADE, and manuscript drafting in the same project — and benefit from blinded dual-reviewer enforcement plus Cohen's kappa IRR out of the box — mapped is the broader fit.
Which is the best tool for meta-analysis?
RevMan (Cochrane) is canonical for intervention meta-analyses inside the Cochrane Library workflow. mapped is broader: an R engine that covers intervention, prognostic, diagnostic test accuracy (mada / SROC), and network meta-analysis (netmeta with league tables and rankograms), plus 13 plot types and 600 DPI exports across six journal presets — all without writing R code.
Which is the best tool for solo researchers and students?
Rayyan's free tier is hard to beat for screening-only workflows. mapped's free tier covers one active project end-to-end with AI-assisted screening and basic extraction — useful for a thesis review. For a serious review with meta-analysis or GRADE, the Mapped Project tier (list $119/project, currently $79 launch pricing) is typically cheaper than Covidence's annual subscription.
Which is the best tool for institutions and research groups?
EPPI-Reviewer and Covidence both have established institutional licensing. mapped's Custom Enterprise plan adds SSO, unlimited projects and team members, dedicated onboarding, and per-institution pricing negotiated rather than per-user. The Cohen's kappa IRR transparency and immutable audit trail are increasingly required for IRB and journal submission.
What's free across these tools?
Rayyan has a generous free tier (limited features). RevMan is free for non-commercial / Cochrane use. Covidence offers a free trial only. EPPI-Reviewer is paid (with academic discounts). mapped's free tier covers one active project with up to 1,000 screening citations, 200 AI-assisted screenings, and PRISMA auto-generation.
How do I migrate an existing review to mapped?
Import your search results as RIS or BibTeX (compatible with exports from any of the four tools above). Screening decisions can be uploaded as CSV; extraction templates can be reproduced from your existing forms. For projects with substantial in-flight work, contact us at /contact and we'll help structure the migration.

Ready to try mapped?

Free tier — no credit card. The full eight-step workflow, one project at a time.

Start freeSee pricing